Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.72 |
| ▸ | HTR1A | P08908 | 3/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 5/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450791 | 1.00 | HTR2A (0.72) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| SCHEMBL27084881 | 0.88 | MTNR1A (0.74) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| Dimethylamine SCHEMBL28487741 | 0.87 | HTR2A (0.67) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| SCHEMBL29629305 | 0.84 | HTR2A (0.71) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| SCHEMBL15732778 | 0.84 | HTR2A (0.71) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| SCHEMBL31742680 | 0.84 | HTR2A (0.70) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| Psilocybin SCHEMBL20898148 | 0.84 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| SCHEMBL25802778 | 0.84 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| Psilocybin SCHEMBL158945 | 0.84 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BMTNR1A | |
| SCHEMBL25541553 | 0.84 | HTR2A (0.70) | HTR2AHTR1AHTR2CHTR2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497637-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-16 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| CN-114599355-A | Method for treating psychological and cerebral diseases | 马里兰大学巴尔的摩分校 | 2022-06-07 | — | — | CN | claimed |
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | Convergent Health Sciences LLC: (US) | 2026-04-28 | — | — | US | disclosed |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | APOAPSIS HOLDINGS, LLC (US) | 2026-04-14 | — | — | US | disclosed |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260049056-A1 | PSILOCYBIN DERIVATIVES | CAAMTECH, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12503713-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-12497637-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-16 | — | — | US | disclosed |
| CN-116761599-B | Deuterated or partially deuterated N, N-dimethyltryptamine compounds | 赛本英国有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230000885-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4099995-A1 | PSYCHEDELIC TREATMENT FOR HEADACHE DISORDERS | Yale University (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022235587-A1 | LIPID PRODRUGS OF TRYPTAMINE AND PHENETHYLAMINE PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-114599355-A | Method for treating psychological and cerebral diseases | 马里兰大学巴尔的摩分校 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | PLCB1, PHKG1, PLCB3 | HTR2A 105/4885HTR1A 91/4885HTR2C 39/4885 |
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | SLC6A3, SLC6A2, HTR2C | HTR2A 31/4885HTR1A 27/4885HTR2C 3/4885 |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | OPRM1, DRD3, SLC6A3 | HTR2A 22/4885HTR1A 32/4885HTR2C 10/4885 |
| US-20260049056-A1 | PSILOCYBIN DERIVATIVES | OTC, PSAT1, TPH1 | HTR2A 340/4885HTR1A 131/4885HTR2C 48/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | HTR2A 11/4885HTR1A 25/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.